Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Genuine Parts Company (GPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Genuine Parts Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Genuine Parts Company trades at $125.62 (market cap $17.29B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.3× Genuine Parts Company's market cap, and Genuine Parts Company pays a 3.38% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GPC | |
|---|---|---|
Market Cap | $39.89B | $17.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $149.26 |
52-Week Low | $278.09 | $92.47 |
Enterprise Value | $38.15B | $23.50B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GPC trades at $125.62, up 1.09% with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $24.3B in 2025, though net margins compressed to 0.24%. Analyst consensus is mixed with 43% buy ratings and a $133 price target. Recent news highlights GPC's 70-year dividend growth streak and upcoming Q2 2026 earnings report on July 21, 2026.
GPC offers income stability with its Dividend King status but faces profitability challenges. The stock trades near analyst targets with moderate upside potential. Key risks include margin pressure from rising costs and competitive threats in auto parts distribution. Institutional sentiment remains cautiously optimistic given the stable dividend history amid earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
